[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQmcOy85voIZWF33qpVEHqHQHxxoCfWspytJNh2Q0xxY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Hospital Universitari Vall d'Hebron Research Institute",[4],265,false,51,16,129342,14,203,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Healthy",17,{"name":18,"count":19},"Fibromyalgia",8,{"name":21,"count":22},"Dyspepsia",7,{"name":24,"count":25},"Acute Respiratory Failure",5,{"name":27,"count":25},"Stroke",{"name":29,"count":25},"Irritable Bowel Syndrome",{"name":31,"count":32},"Sickle Cell Disease",4,{"name":34,"count":32},"Hepatic Encephalopathy",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06503848","Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I","2024-12","Sumatriptan",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07206095","Integrative Diagnosis for SCD and Other RADs","2025-05-25","Analysis of genetic modifiers",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06435481","Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics","2025-09","3D printed chewable formulation of hydrocortisone",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05622539","Validate: Trustworthy AI to Improve Acute Stroke Outcomes","2025-12","CONVENTIONAL ACUTE STROKE MANAGEMENT",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07159750","Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine","2026-01","CGRP antibody or gepant",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06434753","Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.","2026-03-02","Zinc Acexamate",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06398028","The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound.","2026-03-19","Indocyanine green",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07422519","Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression","2026-12-15","Esketamine Treatment as Usual",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT07607197","Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)","2027-05","Autologous Hematopoietic Stem Cell Transplantation",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06676696","Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure","2028-01-31","Continue low dose calcineurin inhibitor",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,119,145,163,187,205,235,253,276,303,326,348,369,393,422,461,499,521,557,604,630,657,675,693,718,743,761,786,804,829,847,871,889,913,940,958,987,1005,1030,1048,1066,1084,1102,1129,1156,1174,1203,1221,1248,1266,1284,1302,1320,1338,1356,1381,1408,1433,1457,1483,1501,1527,1545,1571,1597,1621,1645,1670,1695,1721,1739,1775,1800,1818,1836,1854,1880,1906,1924,1942,1976,2003,2028,2053,2080,2098,2116,2140,2163,2188,2213],{"intervention":70,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":117},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":69},[108],{"nctId":67,"briefTitle":68,"status":109,"phases":110,"primaryCompletion":69,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"RECRUITING",[91],"2028-03-19","2023-08-19",173,[115],"Liver Tumor; Surgery",[70],{"trials":118,"activeCount":99},[],{"intervention":85,"totalTrials":95,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":143},{"trials":122,"activeCount":99},[],{"trials":124,"activeCount":99},[],{"trials":126,"activeCount":99},[],{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":95,"soonestReadout":84},[131],{"nctId":82,"briefTitle":83,"status":109,"phases":132,"primaryCompletion":84,"completion":84,"start":133,"enrollment":134,"conditions":135,"interventions":141},[91],"2024-01-22",202,[136,137,138,139,140],"Renal Failure , Chronic","Graft Failure","Graft Rejection","Allograft","Renal Failure Chronic Requiring Dialysis",[85,142],"Calcineurin inhibitor withdrawal at 6 months",{"trials":144,"activeCount":99},[],{"intervention":142,"totalTrials":95,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":161},{"trials":148,"activeCount":99},[],{"trials":150,"activeCount":99},[],{"trials":152,"activeCount":99},[],{"trials":154,"activeCount":99},[],{"trials":156,"activeCount":95,"soonestReadout":84},[157],{"nctId":82,"briefTitle":83,"status":109,"phases":158,"primaryCompletion":84,"completion":84,"start":133,"enrollment":134,"conditions":159,"interventions":160},[91],[136,137,138,139,140],[85,142],{"trials":162,"activeCount":99},[],{"intervention":50,"totalTrials":95,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":185},{"trials":166,"activeCount":99},[],{"trials":168,"activeCount":99},[],{"trials":170,"activeCount":99},[],{"trials":172,"activeCount":99},[],{"trials":174,"activeCount":95,"soonestReadout":49},[175],{"nctId":47,"briefTitle":48,"status":176,"phases":177,"primaryCompletion":49,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NOT_YET_RECRUITING",[91],"2026-09","2024-09",35,[182],"Adrenal Insufficiency",[50,184],"Oral suspension of hydrocortisone",{"trials":186,"activeCount":99},[],{"intervention":184,"totalTrials":95,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":203},{"trials":190,"activeCount":99},[],{"trials":192,"activeCount":99},[],{"trials":194,"activeCount":99},[],{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":95,"soonestReadout":49},[199],{"nctId":47,"briefTitle":48,"status":176,"phases":200,"primaryCompletion":49,"completion":178,"start":179,"enrollment":180,"conditions":201,"interventions":202},[91],[182],[50,184],{"trials":204,"activeCount":99},[],{"intervention":206,"totalTrials":95,"cells":207},"Early Discontinuation of Antibiotics",{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":233},{"trials":209,"activeCount":99},[],{"trials":211,"activeCount":99},[],{"trials":213,"activeCount":99},[],{"trials":215,"activeCount":99},[],{"trials":217,"activeCount":95,"soonestReadout":222},[218],{"nctId":219,"briefTitle":220,"status":176,"phases":221,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":231},"NCT07590648","Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia",[91],"2028-07-01","2026-06-01",136,[226,227,228,229,230],"Febrile Neutropenia (FN)","Pediatric Cancer","Hematologic Malignancies","Solid Tumors","Invasive Bacterial Infection",[206,232],"Standard Antibiotic Continuation Strategy",{"trials":234,"activeCount":99},[],{"intervention":232,"totalTrials":95,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":251},{"trials":238,"activeCount":99},[],{"trials":240,"activeCount":99},[],{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":99},[],{"trials":246,"activeCount":95,"soonestReadout":222},[247],{"nctId":219,"briefTitle":220,"status":176,"phases":248,"primaryCompletion":222,"completion":222,"start":223,"enrollment":224,"conditions":249,"interventions":250},[91],[226,227,228,229,230],[206,232],{"trials":252,"activeCount":99},[],{"intervention":65,"totalTrials":95,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":272,"NA":274},{"trials":256,"activeCount":99},[],{"trials":258,"activeCount":99},[],{"trials":260,"activeCount":99},[],{"trials":262,"activeCount":95,"soonestReadout":64},[263],{"nctId":62,"briefTitle":63,"status":109,"phases":264,"primaryCompletion":64,"completion":64,"start":265,"enrollment":266,"conditions":267,"interventions":271},[90],"2022-10-02",300,[268,269,270],"Advanced Chronic Liver Disease","Portal Hypertension","Hepatocellular Carcinoma",[65],{"trials":273,"activeCount":99},[],{"trials":275,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":297,"PHASE4":299,"NA":301},{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":95,"soonestReadout":79},[284],{"nctId":77,"briefTitle":78,"status":109,"phases":285,"primaryCompletion":79,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":296},[88,89],"2028-06","2024-02-01",10,[290,291,292,293,294,295],"Kidney Failure, Chronic","Kidney Transplantation","Alloimmunization","HLA Sensitization","End Stage Cronic Kidney Disease","Highly Sensitized Patients Awaiting Kidney Transplant",[80],{"trials":298,"activeCount":99},[],{"trials":300,"activeCount":99},[],{"trials":302,"activeCount":99},[],{"intervention":60,"totalTrials":95,"cells":304},{"EARLY_PHASE1":305,"PHASE1":307,"PHASE2":309,"PHASE3":311,"PHASE4":313,"NA":315},{"trials":306,"activeCount":99},[],{"trials":308,"activeCount":99},[],{"trials":310,"activeCount":99},[],{"trials":312,"activeCount":99},[],{"trials":314,"activeCount":99},[],{"trials":316,"activeCount":95,"soonestReadout":59},[317],{"nctId":57,"briefTitle":58,"status":109,"phases":318,"primaryCompletion":59,"completion":59,"start":319,"enrollment":320,"conditions":321,"interventions":325},[],"2024-01-02",700,[322,323,324],"Migraine","Episodic Migraine","Chronic Migraine, Headache",[60],{"intervention":55,"totalTrials":95,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":329,"activeCount":99},[],{"trials":331,"activeCount":99},[],{"trials":333,"activeCount":99},[],{"trials":335,"activeCount":99},[],{"trials":337,"activeCount":99},[],{"trials":339,"activeCount":95,"soonestReadout":54},[340],{"nctId":52,"briefTitle":53,"status":109,"phases":341,"primaryCompletion":54,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},[],"2026-05","2024-07-31",218,[346],"Acute Stroke",[55],{"intervention":40,"totalTrials":95,"cells":349},{"EARLY_PHASE1":350,"PHASE1":352,"PHASE2":354,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":351,"activeCount":99},[],{"trials":353,"activeCount":99},[],{"trials":355,"activeCount":99},[],{"trials":357,"activeCount":99},[],{"trials":359,"activeCount":99},[],{"trials":361,"activeCount":95,"soonestReadout":39},[362],{"nctId":37,"briefTitle":38,"status":109,"phases":363,"primaryCompletion":39,"completion":39,"start":364,"enrollment":365,"conditions":366,"interventions":368},[],"2024-01-25",108,[367],"Migraine Disorders",[40],{"intervention":75,"totalTrials":95,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":379,"NA":381},{"trials":372,"activeCount":99},[],{"trials":374,"activeCount":99},[],{"trials":376,"activeCount":99},[],{"trials":378,"activeCount":99},[],{"trials":380,"activeCount":99},[],{"trials":382,"activeCount":95,"soonestReadout":74},[383],{"nctId":72,"briefTitle":73,"status":109,"phases":384,"primaryCompletion":74,"completion":74,"start":385,"enrollment":386,"conditions":387,"interventions":392},[92],"2025-09-18",30,[388,389,390,391],"Depression - Major Depressive Disorder","Depression Disorder","Depression Chronic","Treatment-Resistant Major Depressive Disorder",[75],{"intervention":45,"totalTrials":95,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":99},[],{"trials":402,"activeCount":99},[],{"trials":404,"activeCount":99},[],{"trials":406,"activeCount":95,"soonestReadout":44},[407],{"nctId":42,"briefTitle":43,"status":109,"phases":408,"primaryCompletion":44,"completion":409,"start":410,"enrollment":411,"conditions":412,"interventions":421},[],"2028-05","2020-11-13",200,[31,413,414,415,416,417,418,419,420],"Thalassaemia","Congenital Dyserythropoietic Anemia (CDA)","Enzyme Disorder; Anemia","Spherocytosis, Hereditary","Stomatocytosis","Hemoglobin Disorder","Anemia Due to Membrane Defect","Rare Anemia Disorders",[45],{"intervention":423,"totalTrials":424,"cells":425},"Prednisone",2,{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":444,"PHASE4":446,"NA":459},{"trials":427,"activeCount":99},[],{"trials":429,"activeCount":99},[],{"trials":431,"activeCount":99},[432],{"nctId":433,"briefTitle":434,"status":435,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":442},"NCT02116556","Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis","UNKNOWN",[89],"2016-12","2013-04",29,[441],"Alcoholic Hepatitis",[423,443],"Rifaximin",{"trials":445,"activeCount":99},[],{"trials":447,"activeCount":99},[448],{"nctId":449,"briefTitle":450,"status":435,"phases":451,"primaryCompletion":452,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":458},"NCT04534478","Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19",[91],"2021-05-02","2021-12-15","2020-09-07",120,[457],"COVID-19 Pneumonia",[423],{"trials":460,"activeCount":99},[],{"intervention":462,"totalTrials":424,"cells":463},"Caffeine",{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":485,"NA":497},{"trials":465,"activeCount":99},[],{"trials":467,"activeCount":99},[],{"trials":469,"activeCount":99},[],{"trials":471,"activeCount":99},[472],{"nctId":473,"briefTitle":474,"status":475,"phases":476,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":481,"interventions":483},"NCT00495092","Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients","COMPLETED",[89,90],"2009-12","2010-10","2005-01",85,[482],"Cocaine Related Disorders",[462,484],"Biperiden",{"trials":486,"activeCount":99},[487],{"nctId":488,"briefTitle":489,"status":435,"phases":490,"primaryCompletion":491,"completion":491,"start":492,"enrollment":365,"conditions":493,"interventions":495},"NCT00495183","Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence",[91],"2010-07","2009-01",[494],"Cocaine Dependence",[496,484],"caffeine",{"trials":498,"activeCount":99},[],{"intervention":484,"totalTrials":424,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":513,"NA":519},{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":99},[],{"trials":506,"activeCount":99},[],{"trials":508,"activeCount":99},[509],{"nctId":473,"briefTitle":474,"status":475,"phases":510,"primaryCompletion":477,"completion":478,"start":479,"enrollment":480,"conditions":511,"interventions":512},[89,90],[482],[462,484],{"trials":514,"activeCount":99},[515],{"nctId":488,"briefTitle":489,"status":435,"phases":516,"primaryCompletion":491,"completion":491,"start":492,"enrollment":365,"conditions":517,"interventions":518},[91],[494],[496,484],{"trials":520,"activeCount":99},[],{"intervention":522,"totalTrials":424,"cells":523},"Lenalidomide",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":540,"PHASE4":542,"NA":555},{"trials":525,"activeCount":99},[],{"trials":527,"activeCount":99},[],{"trials":529,"activeCount":99},[530],{"nctId":531,"briefTitle":532,"status":475,"phases":533,"primaryCompletion":534,"completion":534,"start":477,"enrollment":535,"conditions":536,"interventions":538},"NCT01246557","Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment",[88,89],"2014-04",20,[537],"Chronic Lymphatic Leukemia",[522,539],"Dexamethasone",{"trials":541,"activeCount":99},[],{"trials":543,"activeCount":99},[544],{"nctId":545,"briefTitle":546,"status":475,"phases":547,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":554},"NCT01408199","Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus",[91],"2010-08","2011-08","2010-01",15,[553],"Cutaneous Lupus",[522],{"trials":556,"activeCount":99},[],{"intervention":558,"totalTrials":424,"cells":559},"Metronidazole 1 g Intravenous",{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":602},{"trials":561,"activeCount":99},[],{"trials":563,"activeCount":99},[],{"trials":565,"activeCount":99},[],{"trials":567,"activeCount":99},[],{"trials":569,"activeCount":99},[570,585],{"nctId":571,"briefTitle":572,"status":475,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":580},"NCT02505581","Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis",[91],"2017-04","2018-11-10","2015-05",536,[579],"Surgical Wound Infection",[581,582,583,584,558],"Extra dosage - cefuroxime (750mg) I.V","Ciprofloxacin 750 mg","Metronidazole 250 mg","Cefuroxime 1.5 g Intravenous",{"nctId":586,"briefTitle":587,"status":435,"phases":588,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":593,"interventions":596},"NCT04161599","Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial.",[91],"2024-06","2024-07","2022-03-01",968,[594,595],"Wounds and Injuries","Surgery--Complications",[597,598,599,558,600,601],"Cefuroxime (750mg) I.V","Cefuroxime 750mg","Metronidazole 250 MG Oral Tablet [Flagyl]","Cefuroxime 1,5 g Intravenous","Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg\u002F3.5 g\u002F10.97 g",{"trials":603,"activeCount":99},[],{"intervention":605,"totalTrials":95,"cells":606},"Omacor®",{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":613,"PHASE4":615,"NA":628},{"trials":608,"activeCount":99},[],{"trials":610,"activeCount":99},[],{"trials":612,"activeCount":99},[],{"trials":614,"activeCount":99},[],{"trials":616,"activeCount":99},[617],{"nctId":618,"briefTitle":619,"status":435,"phases":620,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":627},"NCT00437099","Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder",[91],"2011-02","2011-09","2009-02",102,[626],"Borderline Personality Disorder.",[605],{"trials":629,"activeCount":99},[],{"intervention":631,"totalTrials":95,"cells":632},"Dolutegravir",{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":655},{"trials":634,"activeCount":99},[],{"trials":636,"activeCount":99},[],{"trials":638,"activeCount":99},[],{"trials":640,"activeCount":99},[],{"trials":642,"activeCount":99},[643],{"nctId":644,"briefTitle":645,"status":475,"phases":646,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":650,"interventions":652},"NCT02513147","HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen",[91],"2016-11","2015-06",44,[651],"HIV-1",[631,653,654,654],"PI","2 NRTI",{"trials":656,"activeCount":99},[],{"intervention":653,"totalTrials":95,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":667,"NA":673},{"trials":660,"activeCount":99},[],{"trials":662,"activeCount":99},[],{"trials":664,"activeCount":99},[],{"trials":666,"activeCount":99},[],{"trials":668,"activeCount":99},[669],{"nctId":644,"briefTitle":645,"status":475,"phases":670,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":671,"interventions":672},[91],[651],[631,653,654,654],{"trials":674,"activeCount":99},[],{"intervention":654,"totalTrials":95,"cells":676},{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":685,"NA":691},{"trials":678,"activeCount":99},[],{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":99},[],{"trials":686,"activeCount":99},[687],{"nctId":644,"briefTitle":645,"status":475,"phases":688,"primaryCompletion":647,"completion":647,"start":648,"enrollment":649,"conditions":689,"interventions":690},[91],[651],[631,653,654,654],{"trials":692,"activeCount":99},[],{"intervention":694,"totalTrials":95,"cells":695},"Simvastatin",{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":716},{"trials":697,"activeCount":99},[],{"trials":699,"activeCount":99},[],{"trials":701,"activeCount":99},[],{"trials":703,"activeCount":99},[],{"trials":705,"activeCount":99},[706],{"nctId":707,"briefTitle":708,"status":475,"phases":709,"primaryCompletion":710,"completion":710,"start":711,"enrollment":712,"conditions":713,"interventions":715},"NCT01073007","Stroke Treatment With Acute Reperfusion and Simvastatin",[91],"2014-06","2009-04",104,[714],"Stroke, Acute",[694],{"trials":717,"activeCount":99},[],{"intervention":719,"totalTrials":95,"cells":720},"Azathioprine",{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":727,"PHASE4":729,"NA":741},{"trials":722,"activeCount":99},[],{"trials":724,"activeCount":99},[],{"trials":726,"activeCount":99},[],{"trials":728,"activeCount":99},[],{"trials":730,"activeCount":99},[731],{"nctId":732,"briefTitle":733,"status":475,"phases":734,"primaryCompletion":735,"completion":735,"start":477,"enrollment":736,"conditions":737,"interventions":739},"NCT01112215","Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations",[91],"2015-12",240,[738],"Systemic Lupus Erythematosus",[719,740],"Enteric-Coated Mycophenolate Sodium",{"trials":742,"activeCount":99},[],{"intervention":740,"totalTrials":95,"cells":744},{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":751,"PHASE4":753,"NA":759},{"trials":746,"activeCount":99},[],{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":99},[],{"trials":752,"activeCount":99},[],{"trials":754,"activeCount":99},[755],{"nctId":732,"briefTitle":733,"status":475,"phases":756,"primaryCompletion":735,"completion":735,"start":477,"enrollment":736,"conditions":757,"interventions":758},[91],[738],[719,740],{"trials":760,"activeCount":99},[],{"intervention":762,"totalTrials":95,"cells":763},"Acetylsalicylic Acid + clopidogrel + acenocoumarol",{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":772,"NA":784},{"trials":765,"activeCount":99},[],{"trials":767,"activeCount":99},[],{"trials":769,"activeCount":99},[],{"trials":771,"activeCount":99},[],{"trials":773,"activeCount":99},[774],{"nctId":775,"briefTitle":776,"status":435,"phases":777,"primaryCompletion":735,"completion":735,"start":778,"enrollment":779,"conditions":780,"interventions":782},"NCT01141153","Anticoagulation in Stent Intervention",[91],"2010-06",304,[781,27],"Atrial Fibrillation",[762,783],"Acetylsalicylic Acid + clopidogrel",{"trials":785,"activeCount":99},[],{"intervention":783,"totalTrials":95,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":802},{"trials":789,"activeCount":99},[],{"trials":791,"activeCount":99},[],{"trials":793,"activeCount":99},[],{"trials":795,"activeCount":99},[],{"trials":797,"activeCount":99},[798],{"nctId":775,"briefTitle":776,"status":435,"phases":799,"primaryCompletion":735,"completion":735,"start":778,"enrollment":779,"conditions":800,"interventions":801},[91],[781,27],[762,783],{"trials":803,"activeCount":99},[],{"intervention":805,"totalTrials":95,"cells":806},"Albumin",{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":813,"PHASE4":815,"NA":827},{"trials":808,"activeCount":99},[],{"trials":810,"activeCount":99},[],{"trials":812,"activeCount":99},[],{"trials":814,"activeCount":99},[],{"trials":816,"activeCount":99},[817],{"nctId":818,"briefTitle":819,"status":475,"phases":820,"primaryCompletion":821,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":825},"NCT00886925","Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis",[91],"2012-07","2009-03",56,[34],[805,826],"Sodium chloride 0.9%",{"trials":828,"activeCount":99},[],{"intervention":826,"totalTrials":95,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":839,"NA":845},{"trials":832,"activeCount":99},[],{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":99},[],{"trials":838,"activeCount":99},[],{"trials":840,"activeCount":99},[841],{"nctId":818,"briefTitle":819,"status":475,"phases":842,"primaryCompletion":821,"completion":821,"start":822,"enrollment":823,"conditions":843,"interventions":844},[91],[34],[805,826],{"trials":846,"activeCount":99},[],{"intervention":848,"totalTrials":95,"cells":849},"efavirenz + emtricitabina + tenofovir",{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":869},{"trials":851,"activeCount":99},[],{"trials":853,"activeCount":99},[],{"trials":855,"activeCount":99},[],{"trials":857,"activeCount":99},[],{"trials":859,"activeCount":99},[860],{"nctId":861,"briefTitle":862,"status":475,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":386,"conditions":866,"interventions":867},"NCT02547844","Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla",[91],"2016-10","2015-09",[651],[848,868],"rilpivirina + emtricitabina + tenofovir",{"trials":870,"activeCount":99},[],{"intervention":868,"totalTrials":95,"cells":872},{"EARLY_PHASE1":873,"PHASE1":875,"PHASE2":877,"PHASE3":879,"PHASE4":881,"NA":887},{"trials":874,"activeCount":99},[],{"trials":876,"activeCount":99},[],{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[],{"trials":882,"activeCount":99},[883],{"nctId":861,"briefTitle":862,"status":475,"phases":884,"primaryCompletion":864,"completion":864,"start":865,"enrollment":386,"conditions":885,"interventions":886},[91],[651],[848,868],{"trials":888,"activeCount":99},[],{"intervention":890,"totalTrials":95,"cells":891},"Ribavirin",{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":900,"NA":911},{"trials":893,"activeCount":99},[],{"trials":895,"activeCount":99},[],{"trials":897,"activeCount":99},[],{"trials":899,"activeCount":99},[],{"trials":901,"activeCount":99},[902],{"nctId":903,"briefTitle":904,"status":905,"phases":906,"primaryCompletion":907,"completion":907,"start":735,"enrollment":25,"conditions":908,"interventions":910},"NCT02558114","Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.","TERMINATED",[91],"2018-11",[909],"Hepatitis E",[890],{"trials":912,"activeCount":99},[],{"intervention":914,"totalTrials":95,"cells":915},"Varenicline",{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":924,"NA":938},{"trials":917,"activeCount":99},[],{"trials":919,"activeCount":99},[],{"trials":921,"activeCount":99},[],{"trials":923,"activeCount":99},[],{"trials":925,"activeCount":99},[926],{"nctId":927,"briefTitle":928,"status":929,"phases":930,"primaryCompletion":931,"completion":931,"start":932,"enrollment":99,"conditions":933,"interventions":936},"NCT03809897","Varenicline for Smoking Cessation in Hospitalized Patients With Psychiatric Disorders","WITHDRAWN",[91],"2020-04","2019-01",[934,935],"Tobacco Use Cessation","Psychiatric Disorders",[914,937],"Nicotine patch",{"trials":939,"activeCount":99},[],{"intervention":937,"totalTrials":95,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":948,"PHASE4":950,"NA":956},{"trials":943,"activeCount":99},[],{"trials":945,"activeCount":99},[],{"trials":947,"activeCount":99},[],{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":99},[952],{"nctId":927,"briefTitle":928,"status":929,"phases":953,"primaryCompletion":931,"completion":931,"start":932,"enrollment":99,"conditions":954,"interventions":955},[91],[934,935],[914,937],{"trials":957,"activeCount":99},[],{"intervention":959,"totalTrials":95,"cells":960},"Tranexamic Acid",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":985},{"trials":962,"activeCount":99},[],{"trials":964,"activeCount":99},[],{"trials":966,"activeCount":99},[],{"trials":968,"activeCount":99},[],{"trials":970,"activeCount":99},[971],{"nctId":972,"briefTitle":973,"status":475,"phases":974,"primaryCompletion":975,"completion":975,"start":976,"enrollment":977,"conditions":978,"interventions":983},"NCT01136590","Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery",[91],"2014-05","2010-09",96,[979,980,981,982],"Spinal Fusion","Antifibrinolytic Agents","Hemorrhage","Blood Transfusion",[959,984],"fisiologic serum",{"trials":986,"activeCount":99},[],{"intervention":984,"totalTrials":95,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":997,"NA":1003},{"trials":990,"activeCount":99},[],{"trials":992,"activeCount":99},[],{"trials":994,"activeCount":99},[],{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":99},[999],{"nctId":972,"briefTitle":973,"status":475,"phases":1000,"primaryCompletion":975,"completion":975,"start":976,"enrollment":977,"conditions":1001,"interventions":1002},[91],[979,980,981,982],[959,984],{"trials":1004,"activeCount":99},[],{"intervention":1006,"totalTrials":95,"cells":1007},"Human albumin",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1014,"PHASE4":1016,"NA":1028},{"trials":1009,"activeCount":99},[],{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[],{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":99},[1018],{"nctId":1019,"briefTitle":1020,"status":435,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1027},"NCT02401490","Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy",[91],"2018-03","2015-04",128,[34,1026],"Cirrhosis",[1006],{"trials":1029,"activeCount":99},[],{"intervention":581,"totalTrials":95,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1046},{"trials":1033,"activeCount":99},[],{"trials":1035,"activeCount":99},[],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":99},[1042],{"nctId":571,"briefTitle":572,"status":475,"phases":1043,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":1044,"interventions":1045},[91],[579],[581,582,583,584,558],{"trials":1047,"activeCount":99},[],{"intervention":582,"totalTrials":95,"cells":1049},{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1058,"NA":1064},{"trials":1051,"activeCount":99},[],{"trials":1053,"activeCount":99},[],{"trials":1055,"activeCount":99},[],{"trials":1057,"activeCount":99},[],{"trials":1059,"activeCount":99},[1060],{"nctId":571,"briefTitle":572,"status":475,"phases":1061,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":1062,"interventions":1063},[91],[579],[581,582,583,584,558],{"trials":1065,"activeCount":99},[],{"intervention":583,"totalTrials":95,"cells":1067},{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1074,"PHASE4":1076,"NA":1082},{"trials":1069,"activeCount":99},[],{"trials":1071,"activeCount":99},[],{"trials":1073,"activeCount":99},[],{"trials":1075,"activeCount":99},[],{"trials":1077,"activeCount":99},[1078],{"nctId":571,"briefTitle":572,"status":475,"phases":1079,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":1080,"interventions":1081},[91],[579],[581,582,583,584,558],{"trials":1083,"activeCount":99},[],{"intervention":584,"totalTrials":95,"cells":1085},{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1094,"NA":1100},{"trials":1087,"activeCount":99},[],{"trials":1089,"activeCount":99},[],{"trials":1091,"activeCount":99},[],{"trials":1093,"activeCount":99},[],{"trials":1095,"activeCount":99},[1096],{"nctId":571,"briefTitle":572,"status":475,"phases":1097,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":1098,"interventions":1099},[91],[579],[581,582,583,584,558],{"trials":1101,"activeCount":99},[],{"intervention":1103,"totalTrials":95,"cells":1104},"Intrapleurally Alteplase vs Intrapleurally Urokinase",{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1127},{"trials":1106,"activeCount":99},[],{"trials":1108,"activeCount":99},[],{"trials":1110,"activeCount":99},[],{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[1115],{"nctId":1116,"briefTitle":1117,"status":475,"phases":1118,"primaryCompletion":1119,"completion":1119,"start":1120,"enrollment":1121,"conditions":1122,"interventions":1126},"NCT01246453","Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema",[91],"2010-12","2003-12",204,[1123,1124,1125],"Empyema, Pleural","Pleural Effusion","Pleural Diseases",[1103],{"trials":1128,"activeCount":99},[],{"intervention":1130,"totalTrials":95,"cells":1131},"Liraglutide",{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1140,"NA":1154},{"trials":1133,"activeCount":99},[],{"trials":1135,"activeCount":99},[],{"trials":1137,"activeCount":99},[],{"trials":1139,"activeCount":99},[],{"trials":1141,"activeCount":99},[1142],{"nctId":1143,"briefTitle":1144,"status":435,"phases":1145,"primaryCompletion":1146,"completion":1147,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1152},"NCT02501850","The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)",[91],"2015-07","2015-10","2014-10",40,[1151],"Diabetes Mellitus Type 2",[1130,1153],"metformin",{"trials":1155,"activeCount":99},[],{"intervention":1153,"totalTrials":95,"cells":1157},{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1166,"NA":1172},{"trials":1159,"activeCount":99},[],{"trials":1161,"activeCount":99},[],{"trials":1163,"activeCount":99},[],{"trials":1165,"activeCount":99},[],{"trials":1167,"activeCount":99},[1168],{"nctId":1143,"briefTitle":1144,"status":435,"phases":1169,"primaryCompletion":1146,"completion":1147,"start":1148,"enrollment":1149,"conditions":1170,"interventions":1171},[91],[1151],[1130,1153],{"trials":1173,"activeCount":99},[],{"intervention":1175,"totalTrials":95,"cells":1176},"escitalopram",{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1185,"NA":1201},{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"trials":1182,"activeCount":99},[],{"trials":1184,"activeCount":99},[],{"trials":1186,"activeCount":99},[1187],{"nctId":1188,"briefTitle":1189,"status":435,"phases":1190,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1195,"interventions":1199},"NCT00209807","Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder",[91],"2009-06","2011-04","2005-09",42,[1196,1197,1198],"Major Depression","Pain","Abdominal Pain",[1175,1200],"Reboxetine",{"trials":1202,"activeCount":99},[],{"intervention":1200,"totalTrials":95,"cells":1204},{"EARLY_PHASE1":1205,"PHASE1":1207,"PHASE2":1209,"PHASE3":1211,"PHASE4":1213,"NA":1219},{"trials":1206,"activeCount":99},[],{"trials":1208,"activeCount":99},[],{"trials":1210,"activeCount":99},[],{"trials":1212,"activeCount":99},[],{"trials":1214,"activeCount":99},[1215],{"nctId":1188,"briefTitle":1189,"status":435,"phases":1216,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":1194,"conditions":1217,"interventions":1218},[91],[1196,1197,1198],[1175,1200],{"trials":1220,"activeCount":99},[],{"intervention":1222,"totalTrials":95,"cells":1223},"Fisiogen Ferro Forte",{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1232,"NA":1246},{"trials":1225,"activeCount":99},[],{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":99},[1234],{"nctId":1235,"briefTitle":1236,"status":475,"phases":1237,"primaryCompletion":1147,"completion":1238,"start":1239,"enrollment":1149,"conditions":1240,"interventions":1244},"NCT02390921","The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron",[91],"2015-11","2015-02",[1241,1242,1243],"Liposomated Iron","Y-de-Roux Gastric By-Pass","Parenteral Iron Therapy",[1222,1245],"Venofer",{"trials":1247,"activeCount":99},[],{"intervention":1245,"totalTrials":95,"cells":1249},{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1264},{"trials":1251,"activeCount":99},[],{"trials":1253,"activeCount":99},[],{"trials":1255,"activeCount":99},[],{"trials":1257,"activeCount":99},[],{"trials":1259,"activeCount":99},[1260],{"nctId":1235,"briefTitle":1236,"status":475,"phases":1261,"primaryCompletion":1147,"completion":1238,"start":1239,"enrollment":1149,"conditions":1262,"interventions":1263},[91],[1241,1242,1243],[1222,1245],{"trials":1265,"activeCount":99},[],{"intervention":597,"totalTrials":95,"cells":1267},{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1274,"PHASE4":1276,"NA":1282},{"trials":1269,"activeCount":99},[],{"trials":1271,"activeCount":99},[],{"trials":1273,"activeCount":99},[],{"trials":1275,"activeCount":99},[],{"trials":1277,"activeCount":99},[1278],{"nctId":586,"briefTitle":587,"status":435,"phases":1279,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":1280,"interventions":1281},[91],[594,595],[597,598,599,558,600,601],{"trials":1283,"activeCount":99},[],{"intervention":598,"totalTrials":95,"cells":1285},{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1292,"PHASE4":1294,"NA":1300},{"trials":1287,"activeCount":99},[],{"trials":1289,"activeCount":99},[],{"trials":1291,"activeCount":99},[],{"trials":1293,"activeCount":99},[],{"trials":1295,"activeCount":99},[1296],{"nctId":586,"briefTitle":587,"status":435,"phases":1297,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":1298,"interventions":1299},[91],[594,595],[597,598,599,558,600,601],{"trials":1301,"activeCount":99},[],{"intervention":599,"totalTrials":95,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1312,"NA":1318},{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[1314],{"nctId":586,"briefTitle":587,"status":435,"phases":1315,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":1316,"interventions":1317},[91],[594,595],[597,598,599,558,600,601],{"trials":1319,"activeCount":99},[],{"intervention":600,"totalTrials":95,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1330,"NA":1336},{"trials":1323,"activeCount":99},[],{"trials":1325,"activeCount":99},[],{"trials":1327,"activeCount":99},[],{"trials":1329,"activeCount":99},[],{"trials":1331,"activeCount":99},[1332],{"nctId":586,"briefTitle":587,"status":435,"phases":1333,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":1334,"interventions":1335},[91],[594,595],[597,598,599,558,600,601],{"trials":1337,"activeCount":99},[],{"intervention":601,"totalTrials":95,"cells":1339},{"EARLY_PHASE1":1340,"PHASE1":1342,"PHASE2":1344,"PHASE3":1346,"PHASE4":1348,"NA":1354},{"trials":1341,"activeCount":99},[],{"trials":1343,"activeCount":99},[],{"trials":1345,"activeCount":99},[],{"trials":1347,"activeCount":99},[],{"trials":1349,"activeCount":99},[1350],{"nctId":586,"briefTitle":587,"status":435,"phases":1351,"primaryCompletion":589,"completion":590,"start":591,"enrollment":592,"conditions":1352,"interventions":1353},[91],[594,595],[597,598,599,558,600,601],{"trials":1355,"activeCount":99},[],{"intervention":1357,"totalTrials":95,"cells":1358},"Eplerenone",{"EARLY_PHASE1":1359,"PHASE1":1361,"PHASE2":1363,"PHASE3":1365,"PHASE4":1367,"NA":1379},{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":99},[],{"trials":1366,"activeCount":99},[],{"trials":1368,"activeCount":99},[1369],{"nctId":1370,"briefTitle":1371,"status":475,"phases":1372,"primaryCompletion":1119,"completion":1119,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1378},"NCT00703352","Eplerenone in Systemic Right Ventricle",[91],"2008-07",26,[1376,1377],"Transposition of Great Vessels","Atrial Switch Procedure",[1357],{"trials":1380,"activeCount":99},[],{"intervention":1382,"totalTrials":95,"cells":1383},"Enoxaparin",{"EARLY_PHASE1":1384,"PHASE1":1386,"PHASE2":1388,"PHASE3":1390,"PHASE4":1404,"NA":1406},{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":99},[],{"trials":1389,"activeCount":99},[],{"trials":1391,"activeCount":99},[1392],{"nctId":1393,"briefTitle":1394,"status":475,"phases":1395,"primaryCompletion":1396,"completion":437,"start":1397,"enrollment":1398,"conditions":1399,"interventions":1403},"NCT01388322","Low Weight Heparin prOphylaxis for Placental-Mediated Complications of PrEgnancy",[90],"2016-06","2012-03",361,[1400,1401,1402],"High Risk Pregnant Women","Placental Insufficiency","Preeclampsia",[1382],{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":99},[],{"intervention":1409,"totalTrials":95,"cells":1410},"Vitamin D3",{"EARLY_PHASE1":1411,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1429,"NA":1431},{"trials":1412,"activeCount":99},[],{"trials":1414,"activeCount":99},[],{"trials":1416,"activeCount":99},[],{"trials":1418,"activeCount":99},[1419],{"nctId":1420,"briefTitle":1421,"status":475,"phases":1422,"primaryCompletion":437,"completion":437,"start":1423,"enrollment":411,"conditions":1424,"interventions":1428},"NCT01875757","Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life",[90],"2013-11",[1425,1426,1427],"Acute Bronchitis","Upper Respiratory Tract Infection","Acute Bronchiolitis",[1409],{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[],{"intervention":1434,"totalTrials":95,"cells":1435},"Atorvastatin",{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1442,"PHASE4":1453,"NA":1455},{"trials":1437,"activeCount":99},[],{"trials":1439,"activeCount":99},[],{"trials":1441,"activeCount":99},[],{"trials":1443,"activeCount":99},[1444],{"nctId":1445,"briefTitle":1446,"status":475,"phases":1447,"primaryCompletion":1448,"completion":1448,"start":1396,"enrollment":1449,"conditions":1450,"interventions":1452},"NCT02679261","Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve",[90],"2021-02",220,[1451],"Bicuspid Aortic Valve",[1434],{"trials":1454,"activeCount":99},[],{"trials":1456,"activeCount":99},[],{"intervention":1458,"totalTrials":95,"cells":1459},"Rivaroxaban",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1479,"NA":1481},{"trials":1461,"activeCount":99},[],{"trials":1463,"activeCount":99},[],{"trials":1465,"activeCount":99},[],{"trials":1467,"activeCount":99},[1468],{"nctId":1469,"briefTitle":1470,"status":475,"phases":1471,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":1474,"conditions":1475,"interventions":1477},"NCT02926170","Rivaroxaban for Patients With Antiphospholipid Syndrome",[90],"2017-12-31","2013-03-13",190,[1476],"Antiphospholipid Syndrome",[1458,1478],"acenocumarol",{"trials":1480,"activeCount":99},[],{"trials":1482,"activeCount":99},[],{"intervention":1478,"totalTrials":95,"cells":1484},{"EARLY_PHASE1":1485,"PHASE1":1487,"PHASE2":1489,"PHASE3":1491,"PHASE4":1497,"NA":1499},{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":99},[],{"trials":1490,"activeCount":99},[],{"trials":1492,"activeCount":99},[1493],{"nctId":1469,"briefTitle":1470,"status":475,"phases":1494,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":1474,"conditions":1495,"interventions":1496},[90],[1476],[1458,1478],{"trials":1498,"activeCount":99},[],{"trials":1500,"activeCount":99},[],{"intervention":1502,"totalTrials":95,"cells":1503},"platelet-rich plasma",{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1510,"PHASE4":1523,"NA":1525},{"trials":1505,"activeCount":99},[],{"trials":1507,"activeCount":99},[],{"trials":1509,"activeCount":99},[],{"trials":1511,"activeCount":99},[1512],{"nctId":1513,"briefTitle":1514,"status":475,"phases":1515,"primaryCompletion":1516,"completion":1516,"start":1517,"enrollment":1518,"conditions":1519,"interventions":1521},"NCT01381081","Platelet-rich Plasma Intra-articular Knee Injections for Knee Osteoarthritis",[90],"2014-01","2011-07",74,[1520],"Knee Osteoarthritis",[1502,1522],"Corticosteroid",{"trials":1524,"activeCount":99},[],{"trials":1526,"activeCount":99},[],{"intervention":1522,"totalTrials":95,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1541,"NA":1543},{"trials":1530,"activeCount":99},[],{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[],{"trials":1536,"activeCount":99},[1537],{"nctId":1513,"briefTitle":1514,"status":475,"phases":1538,"primaryCompletion":1516,"completion":1516,"start":1517,"enrollment":1518,"conditions":1539,"interventions":1540},[90],[1520],[1502,1522],{"trials":1542,"activeCount":99},[],{"trials":1544,"activeCount":99},[],{"intervention":1546,"totalTrials":95,"cells":1547},"Exenatide",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1567,"NA":1569},{"trials":1549,"activeCount":99},[],{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[1556],{"nctId":1557,"briefTitle":1558,"status":475,"phases":1559,"primaryCompletion":1560,"completion":1561,"start":1562,"enrollment":1563,"conditions":1564,"interventions":1566},"NCT02404376","COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial",[90],"2019-08","2020-06","2016-03",378,[1565],"ST Elevation Acute Myocardial Infarction",[1546],{"trials":1568,"activeCount":99},[],{"trials":1570,"activeCount":99},[],{"intervention":1572,"totalTrials":95,"cells":1573},"Tenecteplase",{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1593,"NA":1595},{"trials":1575,"activeCount":99},[],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[1582],{"nctId":1583,"briefTitle":1584,"status":435,"phases":1585,"primaryCompletion":1586,"completion":1587,"start":1588,"enrollment":1589,"conditions":1590,"interventions":1592},"NCT05626972","Tenecteplase Compared to Alteplase for Patients With Large Vesel Oclusion Suspicion Before Thrombectomy",[90],"2023-05","2024-05","2022-05-27",500,[1591],"Acute Ischemic Stroke",[1572],{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[],{"intervention":1598,"totalTrials":95,"cells":1599},"Sildenafil 20mg oral vs Sildenafil 10mg intravenous",{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1606,"PHASE4":1617,"NA":1619},{"trials":1601,"activeCount":99},[],{"trials":1603,"activeCount":99},[],{"trials":1605,"activeCount":99},[],{"trials":1607,"activeCount":99},[1608],{"nctId":1609,"briefTitle":1610,"status":435,"phases":1611,"primaryCompletion":1612,"completion":1613,"start":622,"enrollment":386,"conditions":1614,"interventions":1616},"NCT01091012","Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension",[90],"2012-12","2013-02",[1615],"Pulmonary Hypertension",[1598],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[],{"intervention":1622,"totalTrials":95,"cells":1623},"Apremilast",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1630,"PHASE4":1641,"NA":1643},{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[],{"trials":1631,"activeCount":99},[1632],{"nctId":1633,"briefTitle":1634,"status":435,"phases":1635,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":823,"conditions":1638,"interventions":1640},"NCT03191539","Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis",[90],"2019-06-14","2017-11-02",[1639],"Arthritis; Psoriasis (Etiology)",[1622],{"trials":1642,"activeCount":99},[],{"trials":1644,"activeCount":99},[],{"intervention":1646,"totalTrials":95,"cells":1647},"Ornithine-phenylacetate",{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1654,"PHASE4":1666,"NA":1668},{"trials":1649,"activeCount":99},[],{"trials":1651,"activeCount":99},[],{"trials":1653,"activeCount":99},[],{"trials":1655,"activeCount":99},[1656],{"nctId":1657,"briefTitle":1658,"status":475,"phases":1659,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1665},"NCT01434108","Effects of the Administration of Ornithine Phenylacetate in Patients With Cirrhosis and Upper Gastrointestinal Bleeding",[89,90],"2015-03","2011-10",48,[1664,1026],"Gastrointestinal Bleeding",[1646],{"trials":1667,"activeCount":99},[],{"trials":1669,"activeCount":99},[],{"intervention":1671,"totalTrials":95,"cells":1672},"ASA-withdrawn group",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1691,"NA":1693},{"trials":1674,"activeCount":99},[],{"trials":1676,"activeCount":99},[],{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[1681],{"nctId":1682,"briefTitle":1683,"status":475,"phases":1684,"primaryCompletion":1685,"completion":1685,"start":1686,"enrollment":1687,"conditions":1688,"interventions":1690},"NCT03741179","Detection of False Positives From First-trimester Preeclampsia Screening (StopPRE) at the Second-trimester of Pregnancy",[90],"2022-01-30","2019-08-20",974,[1689],"Pre-Eclampsia",[1671],{"trials":1692,"activeCount":99},[],{"trials":1694,"activeCount":99},[],{"intervention":1696,"totalTrials":95,"cells":1697},"cidofovir 1% topical ointment",{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1704,"PHASE4":1717,"NA":1719},{"trials":1699,"activeCount":99},[],{"trials":1701,"activeCount":99},[],{"trials":1703,"activeCount":99},[],{"trials":1705,"activeCount":99},[1706],{"nctId":1707,"briefTitle":1708,"status":475,"phases":1709,"primaryCompletion":1710,"completion":1711,"start":1712,"enrollment":365,"conditions":1713,"interventions":1715},"NCT04055142","Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males",[90],"2024-01-11","2024-07-02","2020-09-18",[1714],"High-grade Anal Intraepithelial Neoplasia",[1696,1716],"sinecatechins 10% topical ointment",{"trials":1718,"activeCount":99},[],{"trials":1720,"activeCount":99},[],{"intervention":1716,"totalTrials":95,"cells":1722},{"EARLY_PHASE1":1723,"PHASE1":1725,"PHASE2":1727,"PHASE3":1729,"PHASE4":1735,"NA":1737},{"trials":1724,"activeCount":99},[],{"trials":1726,"activeCount":99},[],{"trials":1728,"activeCount":99},[],{"trials":1730,"activeCount":99},[1731],{"nctId":1707,"briefTitle":1708,"status":475,"phases":1732,"primaryCompletion":1710,"completion":1711,"start":1712,"enrollment":365,"conditions":1733,"interventions":1734},[90],[1714],[1696,1716],{"trials":1736,"activeCount":99},[],{"trials":1738,"activeCount":99},[],{"intervention":1740,"totalTrials":424,"cells":1741},"Benznidazole",{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1769,"PHASE4":1771,"NA":1773},{"trials":1743,"activeCount":99},[],{"trials":1745,"activeCount":99},[],{"trials":1747,"activeCount":99},[1748,1758],{"nctId":1749,"briefTitle":1750,"status":475,"phases":1751,"primaryCompletion":1612,"completion":1752,"start":976,"enrollment":1753,"conditions":1754,"interventions":1756},"NCT01162967","Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole",[89],"2013-03",78,[1755],"Chagas Disease",[1740,1757],"Posaconazole",{"nctId":1759,"briefTitle":1760,"status":475,"phases":1761,"primaryCompletion":1762,"completion":1763,"start":1764,"enrollment":1765,"conditions":1766,"interventions":1768},"NCT03191162","Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.",[89],"2020-09-21","2021-03-16","2017-04-21",238,[1755,1767],"Trypanosoma Cruzi Infection",[1740],{"trials":1770,"activeCount":99},[],{"trials":1772,"activeCount":99},[],{"trials":1774,"activeCount":99},[],{"intervention":1776,"totalTrials":95,"cells":1777},"apomorphine",{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1779,"activeCount":99},[],{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":99},[1784],{"nctId":1785,"briefTitle":1786,"status":435,"phases":1787,"primaryCompletion":477,"completion":778,"start":1788,"enrollment":1789,"conditions":1790,"interventions":1792},"NCT00437177","Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)",[89],"2007-01",50,[1791],"Alcoholism",[1776,1793],"[(123)I] iodobenzamide",{"trials":1795,"activeCount":99},[],{"trials":1797,"activeCount":99},[],{"trials":1799,"activeCount":99},[],{"intervention":1793,"totalTrials":95,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1812,"PHASE4":1814,"NA":1816},{"trials":1803,"activeCount":99},[],{"trials":1805,"activeCount":99},[],{"trials":1807,"activeCount":99},[1808],{"nctId":1785,"briefTitle":1786,"status":435,"phases":1809,"primaryCompletion":477,"completion":778,"start":1788,"enrollment":1789,"conditions":1810,"interventions":1811},[89],[1791],[1776,1793],{"trials":1813,"activeCount":99},[],{"trials":1815,"activeCount":99},[],{"trials":1817,"activeCount":99},[],{"intervention":443,"totalTrials":95,"cells":1819},{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1830,"PHASE4":1832,"NA":1834},{"trials":1821,"activeCount":99},[],{"trials":1823,"activeCount":99},[],{"trials":1825,"activeCount":99},[1826],{"nctId":433,"briefTitle":434,"status":435,"phases":1827,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":1828,"interventions":1829},[89],[441],[423,443],{"trials":1831,"activeCount":99},[],{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[],{"intervention":1757,"totalTrials":95,"cells":1837},{"EARLY_PHASE1":1838,"PHASE1":1840,"PHASE2":1842,"PHASE3":1848,"PHASE4":1850,"NA":1852},{"trials":1839,"activeCount":99},[],{"trials":1841,"activeCount":99},[],{"trials":1843,"activeCount":99},[1844],{"nctId":1749,"briefTitle":1750,"status":475,"phases":1845,"primaryCompletion":1612,"completion":1752,"start":976,"enrollment":1753,"conditions":1846,"interventions":1847},[89],[1755],[1740,1757],{"trials":1849,"activeCount":99},[],{"trials":1851,"activeCount":99},[],{"trials":1853,"activeCount":99},[],{"intervention":1855,"totalTrials":95,"cells":1856},"Rifampin",{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[],{"trials":1862,"activeCount":99},[1863],{"nctId":1864,"briefTitle":1865,"status":435,"phases":1866,"primaryCompletion":1867,"completion":1868,"start":1869,"enrollment":1870,"conditions":1871,"interventions":1873},"NCT04768231","Rifampicin at High Dose for Difficult-to-Treat Tuberculosis",[89],"2022-12-31","2023-12-31","2021-04-01",130,[1872],"Tuberculosis",[1855],{"trials":1875,"activeCount":99},[],{"trials":1877,"activeCount":99},[],{"trials":1879,"activeCount":99},[],{"intervention":1881,"totalTrials":95,"cells":1882},"filgrastim",{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1887,"PHASE3":1900,"PHASE4":1902,"NA":1904},{"trials":1884,"activeCount":99},[],{"trials":1886,"activeCount":99},[],{"trials":1888,"activeCount":99},[1889],{"nctId":1890,"briefTitle":1891,"status":475,"phases":1892,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":1895,"conditions":1896,"interventions":1898},"NCT02931071","Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1",[89],"2018-10","2013-09",13,[1897],"Fanconi Anemia",[1881,1899],"plerixafor",{"trials":1901,"activeCount":99},[],{"trials":1903,"activeCount":99},[],{"trials":1905,"activeCount":99},[],{"intervention":1899,"totalTrials":95,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1909,"activeCount":99},[],{"trials":1911,"activeCount":99},[],{"trials":1913,"activeCount":99},[1914],{"nctId":1890,"briefTitle":1891,"status":475,"phases":1915,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":1895,"conditions":1916,"interventions":1917},[89],[1897],[1881,1899],{"trials":1919,"activeCount":99},[],{"trials":1921,"activeCount":99},[],{"trials":1923,"activeCount":99},[],{"intervention":539,"totalTrials":95,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1936,"PHASE4":1938,"NA":1940},{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[],{"trials":1931,"activeCount":99},[1932],{"nctId":531,"briefTitle":532,"status":475,"phases":1933,"primaryCompletion":534,"completion":534,"start":477,"enrollment":535,"conditions":1934,"interventions":1935},[88,89],[537],[522,539],{"trials":1937,"activeCount":99},[],{"trials":1939,"activeCount":99},[],{"trials":1941,"activeCount":99},[],{"intervention":1943,"totalTrials":424,"cells":1944},"Adalimumab",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1960,"PHASE4":1962,"NA":1964},{"trials":1946,"activeCount":99},[],{"trials":1948,"activeCount":99},[],{"trials":1950,"activeCount":99},[1951],{"nctId":1952,"briefTitle":1953,"status":475,"phases":1954,"primaryCompletion":622,"completion":1661,"start":1955,"enrollment":25,"conditions":1956,"interventions":1959},"NCT01136252","Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration",[89],"2010-05",[1957,1958],"Age-Related Macular Degeneration","Choroidal Neovascularization",[1943],{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[],{"trials":1965,"activeCount":99},[1966],{"nctId":1967,"briefTitle":1968,"status":475,"phases":1969,"primaryCompletion":1970,"completion":1970,"start":1971,"enrollment":1972,"conditions":1973,"interventions":1975},"NCT02539849","Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease",[92],"2017-12-19","2014-12",38,[1974],"Crohn Disease",[1943],{"intervention":1977,"totalTrials":95,"cells":1978},"Oxytocin",{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1983,"PHASE3":1985,"PHASE4":1987,"NA":1989},{"trials":1980,"activeCount":99},[],{"trials":1982,"activeCount":99},[],{"trials":1984,"activeCount":99},[],{"trials":1986,"activeCount":99},[],{"trials":1988,"activeCount":99},[],{"trials":1990,"activeCount":99},[1991],{"nctId":1992,"briefTitle":1993,"status":435,"phases":1994,"primaryCompletion":1995,"start":1996,"enrollment":1997,"conditions":1998,"interventions":2002},"NCT02187874","Timing of Umbilical Cord Occlusion in Premature Babies( \u003C33 w). Delayed vs Early.",[92],"2017-07","2014-07",150,[1999,2000,2001],"Delayed Umbilical Cord Clamping Benefits","Postpartum Haemorrhage","Intraventricular Haemorrhage",[1977],{"intervention":2004,"totalTrials":95,"cells":2005},"Genetic test",{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2012,"PHASE4":2014,"NA":2016},{"trials":2007,"activeCount":99},[],{"trials":2009,"activeCount":99},[],{"trials":2011,"activeCount":99},[],{"trials":2013,"activeCount":99},[],{"trials":2015,"activeCount":99},[],{"trials":2017,"activeCount":99},[2018],{"nctId":2019,"briefTitle":2020,"status":475,"phases":2021,"primaryCompletion":2022,"completion":1660,"start":2023,"enrollment":2024,"conditions":2025,"interventions":2027},"NCT02405949","GENETIC SUSCEPTIBILITY FACTOR AS A PREDICTOR OF TYPE 2 DIABETES REMISSION AND WEIGHT LOSS AFTER BARIATRIC SURGERY",[],"2013-10","2013-07",100,[2026],"Case-control Study",[2004],{"intervention":2029,"totalTrials":95,"cells":2030},"Psychopharmacological treatment",{"EARLY_PHASE1":2031,"PHASE1":2033,"PHASE2":2035,"PHASE3":2037,"PHASE4":2039,"NA":2041},{"trials":2032,"activeCount":99},[],{"trials":2034,"activeCount":99},[],{"trials":2036,"activeCount":99},[],{"trials":2038,"activeCount":99},[],{"trials":2040,"activeCount":99},[],{"trials":2042,"activeCount":99},[2043],{"nctId":2044,"briefTitle":2045,"status":475,"phases":2046,"primaryCompletion":2047,"completion":975,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2052},"NCT02172183","CBT Group for Adolescents With ADHD: a Randomized Controlled Trial",[92],"2014-03","2012-04",119,[2051],"Attention Deficit Hyperactivity Disorder",[2029],{"intervention":2054,"totalTrials":95,"cells":2055},"Remifentanil 1 MG Injection [Ultiva]",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2057,"activeCount":99},[],{"trials":2059,"activeCount":99},[],{"trials":2061,"activeCount":99},[],{"trials":2063,"activeCount":99},[],{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[2068],{"nctId":2069,"briefTitle":2070,"status":475,"phases":2071,"primaryCompletion":2072,"completion":2073,"start":2074,"enrollment":2024,"conditions":2075,"interventions":2077},"NCT05115578","Remifentanil Effect-site Prediction by Algometry",[],"2020-05-15","2020-09-30","2017-03-01",[2076],"Conscious Sedation Failure During Procedure",[2054,2078,2079],"Midazolam 1 MG\u002FML Prefilled Syringe","Saline solution",{"intervention":2078,"totalTrials":95,"cells":2081},{"EARLY_PHASE1":2082,"PHASE1":2084,"PHASE2":2086,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2083,"activeCount":99},[],{"trials":2085,"activeCount":99},[],{"trials":2087,"activeCount":99},[],{"trials":2089,"activeCount":99},[],{"trials":2091,"activeCount":99},[],{"trials":2093,"activeCount":99},[2094],{"nctId":2069,"briefTitle":2070,"status":475,"phases":2095,"primaryCompletion":2072,"completion":2073,"start":2074,"enrollment":2024,"conditions":2096,"interventions":2097},[],[2076],[2054,2078,2079],{"intervention":2079,"totalTrials":95,"cells":2099},{"EARLY_PHASE1":2100,"PHASE1":2102,"PHASE2":2104,"PHASE3":2106,"PHASE4":2108,"NA":2110},{"trials":2101,"activeCount":99},[],{"trials":2103,"activeCount":99},[],{"trials":2105,"activeCount":99},[],{"trials":2107,"activeCount":99},[],{"trials":2109,"activeCount":99},[],{"trials":2111,"activeCount":99},[2112],{"nctId":2069,"briefTitle":2070,"status":475,"phases":2113,"primaryCompletion":2072,"completion":2073,"start":2074,"enrollment":2024,"conditions":2114,"interventions":2115},[],[2076],[2054,2078,2079],{"intervention":2117,"totalTrials":95,"cells":2118},"Canagliflozin 300 MG Oral",{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2123,"PHASE3":2125,"PHASE4":2127,"NA":2129},{"trials":2120,"activeCount":99},[],{"trials":2122,"activeCount":99},[],{"trials":2124,"activeCount":99},[],{"trials":2126,"activeCount":99},[],{"trials":2128,"activeCount":99},[],{"trials":2130,"activeCount":99},[2131],{"nctId":2132,"briefTitle":2133,"status":435,"phases":2134,"primaryCompletion":2135,"completion":1867,"start":2136,"enrollment":1149,"conditions":2137,"interventions":2139},"NCT04720859","Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)",[92],"2019-12-20","2018-01-05",[2138],"Postprandial Hypoglycemia",[2117],{"intervention":2141,"totalTrials":95,"cells":2142},"Anti-TNF",{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2149,"PHASE4":2151,"NA":2153},{"trials":2144,"activeCount":99},[],{"trials":2146,"activeCount":99},[],{"trials":2148,"activeCount":99},[],{"trials":2150,"activeCount":99},[],{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[2155],{"nctId":2156,"briefTitle":2157,"status":435,"phases":2158,"primaryCompletion":2159,"completion":2159,"start":1396,"enrollment":411,"conditions":2160,"interventions":2162},"NCT02804204","Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF",[],"2019-12",[2161],"Rheumatoid Arthritis",[2141],{"intervention":2164,"totalTrials":95,"cells":2165},"noradrenaline\u002Fadrenaline",{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2170,"PHASE3":2172,"PHASE4":2174,"NA":2176},{"trials":2167,"activeCount":99},[],{"trials":2169,"activeCount":99},[],{"trials":2171,"activeCount":99},[],{"trials":2173,"activeCount":99},[],{"trials":2175,"activeCount":99},[],{"trials":2177,"activeCount":99},[2178],{"nctId":2179,"briefTitle":2180,"status":475,"phases":2181,"primaryCompletion":2182,"completion":2183,"start":2182,"enrollment":2184,"conditions":2185,"interventions":2187},"NCT05658120","Reperfusion Syndrome and Vasoplegic Syndrome in Liver Transplant Surgery",[],"2022-12-13","2023-02-18",246,[2186],"Postperfusion Syndrome",[2164],{"intervention":2189,"totalTrials":95,"cells":2190},"Group A",{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2195,"PHASE3":2197,"PHASE4":2199,"NA":2201},{"trials":2192,"activeCount":99},[],{"trials":2194,"activeCount":99},[],{"trials":2196,"activeCount":99},[],{"trials":2198,"activeCount":99},[],{"trials":2200,"activeCount":99},[],{"trials":2202,"activeCount":99},[2203],{"nctId":2204,"briefTitle":2205,"status":475,"phases":2206,"primaryCompletion":2207,"completion":2207,"start":2208,"enrollment":535,"conditions":2209,"interventions":2211},"NCT03383939","Inhaled A1AT in Adult Stable Bronchiectasis",[92],"1999-09-07","1996-06-01",[2210],"Bronchiectasis Adult",[2189,2212],"Group B",{"intervention":2212,"totalTrials":95,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2221,"PHASE4":2223,"NA":2225},{"trials":2216,"activeCount":99},[],{"trials":2218,"activeCount":99},[],{"trials":2220,"activeCount":99},[],{"trials":2222,"activeCount":99},[],{"trials":2224,"activeCount":99},[],{"trials":2226,"activeCount":99},[2227],{"nctId":2204,"briefTitle":2205,"status":475,"phases":2228,"primaryCompletion":2207,"completion":2207,"start":2208,"enrollment":535,"conditions":2229,"interventions":2230},[92],[2210],[2189,2212]]